Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (kupffer cells) | 0.10 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 146 | 0.91 |
| pathways Reactome | 3 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 7931
Sealed predictions
- FCN2 in dopamine neurons, braak+0.09 (p 0.825) → -0.69 (p 0.040)receipt 7938
Swarm cases
receipt 7938: FCN2 in dopamine neurons, braak
- power
- full sample -0.24 (p 0.332, n 18), 95% CI -0.64 to +0.25. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.24 (p 0.332, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.42 (p 0.082, n 18). could be the mix.
- skeptic
- leave-one-out range -0.37 to -0.14, sign flips 0; without severely affected donors -0.24 (p 0.332, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FCN2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts